盲法结局裁定委员会在开放标签随机卒中试验中的附加价值
基于MR CLEAN试验数据,评估盲法结局裁定委员会在开放标签随机卒中试验中对mRS评分误分类及疗效估计的影响。结果显示中央评估者误分类率为10.6%,且两组间无差异,是否使用裁定委员会对疗效估计无实质影响。
要点
- 中央评估者误分类mRS评分为10.6%,两组间分布无差异(P=0.59)。
- 血管内治疗获益在中央评估者(aOR 1.60)与裁定委员会(aOR 1.67)评估下一致。
- 在标准化算法评估下,盲法裁定委员会的附加价值有限。
核心结论
- 中央评估者的误分类小、随机分布于治疗组间,且未影响疗效估计。
- 在采用标准化算法评估且评估者不知晓但未正式盲法的卒中试验中,盲法裁定委员会的附加价值有限。
研究设计与样本
- 基于MR CLEAN试验(多中心随机临床试验,血管内治疗急性缺血性卒中)的数据进行分析。
- 主要结局为90天mRS,由中央评估者通过标准化算法电话访谈评估,并由盲法裁定委员会裁定。
主要发现
- 500例中53例(10.6%)mRS评分被中央评估者误分类。
- 误分类的程度和方向在治疗组间无差异(P=0.59)。
- 血管内治疗获益在中央评估者评估时aOR 1.60(95% CI 1.16-2.21),在裁定委员会评估时aOR 1.67(95% CI 1.21-2.20)。
关键数值与推荐
- 误分类定义为中央评估者对mRS评分分类错误。
- 采用多变量序数逻辑回归评估血管内治疗对mRS的效应。
临床怎么用
- 在采用标准化算法电话评估且评估者不知晓治疗的开放标签卒中试验中,可考虑不设盲法裁定委员会以节省资源。
局限性
- 研究基于MR CLEAN试验数据,结论可能不适用于其他评估方式或结局。
- 中央评估者不知晓但未正式盲法,可能影响误分类程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Blinded outcome assessment in trials with prospective randomized open blinded end point design is challenging. Unblinding can result in misclassified outcomes and biased treatment effect estimates. An outcome adjudication committee assures blinded outcome assessment, but the added value for trials with prospective randomized open blinded end point design and subjective outcomes is unknown. We aimed to assess the degree of misclassification of modified Rankin Scale (mRS) scores by a central assessor and its impact on treatment effect estimates in a stroke trial with prospective randomized open blinded end point design. METHODS: We used data from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). The primary outcome was the mRS at 90 days. Standardized, algorithm-based telephone interviews to assess the mRS were conducted from a central location by an experienced research nurse, unaware but not formally blinded to treatment allocation (central assessor). Masked reports of these interviews were adjudicated by a blinded outcome committee. Misclassification was defined as an incorrect classification of the mRS by the central assessor. The effect of endovascular treatment on the mRS was assessed with multivariable ordinal logistic regression. RESULTS: In MR CLEAN, 53/500 (10.6%) of the mRS scores were misclassified. The degree and direction of misclassification did not differ between treatment arms (P=0.59). Benefit of endovascular treatment was shown on the mRS when scored by the central assessor (adjusted common odds ratio, 1.60 [95% CI, 1.16-2.21]) and the outcome adjudication committee (adjusted common odds ratio, 1.67 [95% CI, 1.21-2.20]). CONCLUSIONS: Misclassification by the central assessor was small, randomly distributed over treatment arms, and did not affect treatment effect estimates. This study suggests that the added value of a blinded outcome adjudication committee is limited in a stroke trial with prospective randomized open blinded end point design applying standardized, algorithm-based outcome assessment by a central assessor, who is unaware but not formally blinded to treatment allocation. Registration: URL: https://www.isrctn.com; Unique identifier: ISRCTN10888758.
引用
- van der Ende NAM, Roozenbeek B, Berkhemer OA, et al. Added Value of a Blinded Outcome Adjudication Committee in an Open-Label Randomized Stroke Trial. Stroke. 2021. PMID: 34607469. doi:10.1161/STROKEAHA.121.035301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。